<SEC-DOCUMENT>0001437749-17-011120.txt : 20170612
<SEC-HEADER>0001437749-17-011120.hdr.sgml : 20170612
<ACCEPTANCE-DATETIME>20170612091341
ACCESSION NUMBER:		0001437749-17-011120
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170612
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170612
DATE AS OF CHANGE:		20170612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		17904719

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mlss20170612_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
	<title>mlss20170612_8k.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 6/12/2017 5:52:30 AM --><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;">
<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>UNITED STATES</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Washington, D.C. 20549</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>FORM 8-K</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>CURRENT REPORT</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Securities Exchange Act of 1934</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Date of Report (Date of earliest event reported) </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>June </b></u><u><b>12</b></u><u><b>,</b></u><u><b> 20</b></u><u><b>1</b></u><u><b>7</b></u></font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>MILESTONE SCIENTIFIC INC.</b></u></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Exact name of Registrant as specified in its charter)</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL1" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 30.3%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Delaware</b></p>
			</td>
			<td style="width: 11.3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 17.8%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>001-14053</b></p>
			</td>
			<td style="width: 14.1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 26.5%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>13-3545623</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 30.3%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(State or other jurisdiction of incorporation)</b></p>
			</td>
			<td style="width: 11.3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 17.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Commission File Number)</b></p>
			</td>
			<td style="width: 14.1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 26.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(IRS Employer Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>220 South Orange Avenue, Livingston Corporate Park, Livingston, New Jersey 07034</b></u></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Address of principal executive office) (Zip Code)</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Registrant&#39;s telephone number, including area code </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>(973) 535-2717</b></u></font></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL2" style="width: 67.3%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 18.5%;">

		<tr>
			<td style="width: 100%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 100%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Former name or former address, if changed since last report)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;] W<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">ritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exchange Act (17 CFR 240.14d-2(b))</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</p>

<p style="margin: 0pt; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt;">Emerging growth company <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;]</font></p>

<p style="margin: 0pt 0pt 0pt 69.2%; text-align: left; text-indent: 18pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">[ &nbsp;]</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 8.01.<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;&nbsp; &nbsp;&nbsp;Other Events.</font></b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">On June 12, 2017, Milestone Scientific Inc. issued a press release announcing that its CompuFlo<sup>&reg;</sup> Epidural Computer Controlled Anesthesia System has received 510(k) clearance from the U.S. Food and Drug Administration. The press release is filed as Exhibit 99.1 hereto.</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 9.01.<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></b></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 16.2pt; font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(d) Exhibits</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 16.2pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL3" style="margin: 0pt auto 0pt 18pt; width: 90%; text-indent: 0px; font-size: 10pt;">

		<tr>
			<td style="width: 12.6%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit</b></p>

			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>No.</b></u></p>
			</td>
			<td style="width: 87.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>Description</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="width: 12.6%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">99<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.1</font></p>
			</td>
			<td style="width: 87.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Press release dated <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">June 12, 2017</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">* * * * *</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">2</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 144pt; text-align: center; text-indent: -144pt; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></p>

<p style="margin: 0pt 0pt 0pt 144pt; text-align: center; text-indent: -144pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Dated: <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">June 12, 2017</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width: 3%;"><b>MILESTONE SCIENTIFIC INC.</b></td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 35%;">&nbsp;</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 35%;">&nbsp;</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">By:</td>
			<td style="width: 35%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">/s/ Joseph D&rsquo;Agostino</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 35%;">Joseph D&rsquo;Agostino</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 35%;">Chief Financial Officer</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 35%;">&nbsp;</td>
			<td style="width: 12%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">3</p>

<p style="margin: 0pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
	<title>ex99-1.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 6/12/2017 5:56:52 AM --><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px;">
<p style="text-align: right; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit 99.1</b></font></p>

<p style="text-align: left; margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><img src="ex99-1img001.jpg" style="width: 196pt; height: 70pt;"></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Contact:</b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">David Waldman or <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Natalya Rudman</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Crescendo Communications, LLC</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Email: <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">mlss@crescendo-ir.com</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Tel: 212-671-1020</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>MILESTONE SCIENTIFIC ANNOUNCES 510(k) </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>FDA</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>CLEARANCE FOR COMPUFLO</b><font style="font-family: Times New Roman, Times, serif; font-size: 12pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b> EPIDURAL INSTRUMENT</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>LIVINGSTON, NJ, </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>June 12</b><b>, 201</b><b>7</b><b> -- </b><b>Milestone Scientific Inc</b><b>. (NYSE</b><b>: </b><b>MLSS</b><b>) </b>today announced that the CompuFlo</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Epidural Computer Controlled Anesthesia System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The CompuFlo</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Epidural System provides anesthesiologists and other Health Care Providers for the first time, the ability to quantitatively determine and document the pressure at the needle tip in real-time. The CompuFlo&reg; Epidural&rsquo;s proprietary DPS Dynamic Pressure Sensing Technology</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&trade;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> (DPS) allows the CompuFlo</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Epidural to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify the epidural space.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&ldquo;We are delighted to receive marketing clearance <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">from the FDA, which is considered globally to be the regulatory gold standard in premarket review,&rdquo; commented Leonard Osser, Chief Executive Officer of Milestone Scientific. &ldquo;I would like to thank all the employees, advisors, key-opinion leaders (KOL) and other stakeholders that were instrumental in helping us to achieve this major milestone.&rdquo;</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&ldquo;Looking ahead, we are now focused on <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">reaching out to the top KOLs in the U.S., as we have been doing successfully across Europe. The CompuFlo&reg; Epidural System&rsquo;s ease of use allows use by medical professionals with varying levels of experience, which further drives the value proposition of this technology. In addition, due to what we see as the device&rsquo;s add-on value proposition, we plan to seek reimbursement codes over and above those already in place for traditional epidural procedures.&rdquo;</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">This <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">clearance was supported by the COMPASS Study (CompuFlo</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Assessment Study), which was a prospective, randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of epidural space verification with the CompuFlo</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Epidural Instrument. The primary objective of the COMPASS study was to determine whether the success rate of performance of lumbar epidural anesthesia with the CompuFlo Epidural to identify the epidural space is equivalent to performance of lumbar epidural anesthesia with the LOR technique. The clinical study enrolled 400 patients, of which two-hundred-forty subjects (240) required epidural procedure as part of the chronic pain management and one-hundred-sixty (160) required epidural procedure for acute pain management during labor and delivery. The CompuFlo&reg; Epidural with Dynamic Pressure Sensing Technology resulted in the anesthesiologists objectively identifying the epidural space with 99% success on the first attempt. The COMPASS study involved use of the CompuFlo Epidural in 21 obese subjects (BMI &gt; 31), with performance in this group found to be comparable to the performance seen in patients with lower BMIs. However due to the relatively small sample size of obese patients studied, the safety and effectiveness profile in this subgroup of patients is not fully known. </font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Based on the nonclinical and clinical tests conducted, it was demonstrated the the CompuFlo Epidural device is as safe, as effective and performs as well as or better than the legally marketed predicate devices<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The overall results of the COMPASS study demonstrated that the CompuFlo<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>&reg;</sup></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Epidural can serve as an everyday epidural needle placement confirmation solution.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>About Milestone Scientific Inc.</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Milestone Scientific Inc. (<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone&#39;s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: <u>www.milestonescientific.com</u>.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The CompuFlo&reg; Epidural Computer Controlled Anesthesia System is intended for use with an epidural needle for the real-time verification of needle tip placement in the lumbar epidural space in patients over age of 18 who are required to have epidural needle placement as part of a medically necessary, in-patient or out-patient procedure, as established<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> by their Health Care Provider. Once Health Care Provider verifies the epidural needle placement in the lumbar epidural space, CompuFlo&reg; Epidural Computer Controlled Anesthesia System is disconnected and the HCP continues with the medical procedure.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The CompuFlo Epidural is contraindicated <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">in the following situations:</font></p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB1" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">The CompuFlo Epidural must not be used in situations when epidural access is medically contraindicated as established by Health Care Provider.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB2" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">The CompuFlo Epidural must not be used on a patient that has a skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) in their lumbar region greater than 4 cm<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><sup>2</sup>. </font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB3" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">T<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">he CompuFlo Epidural must not be used on a patient who had prior back surgery in lumbar area that would prevent epidural access.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB4" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">The CompuFlo Epidural System is not intended to be <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">used to Infuse Medication. The safety and effectiveness of infusing medication has not been evaluated.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><i><b>Safe Harbor Statement</b></i></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><i>This press release contains forward-looking statements regarding the timing and financial impact of Milestone&#39;s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone&#39;s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone&#39;s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone&#39;s Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management&#39;s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.</i></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"># # #</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1img001.jpg
<TEXT>
begin 644 ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !> 08# 2(  A$! Q$!_\0
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ME]X6TS49O,N4WGWH52T^>P<MU8\K\-?&+PMH7@VSMKBTUB:YBA16CBTV7J%
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MIUH3L,Y/P7X@M_$FLZIJ=E)*ID6&.6WF)W6\BA@R%3]U@>OKP:R/$%K)I_Q
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
